Sports medicine company Fusionetics reported on Friday the receipt of capital investment from Stella Development.
According to Fusionetics, it will use the capital primarily to fuel growth of its Fusionetics system in the health care sector. Its performance health system is revolutionizing how technology can intersect with health care. It is designed to reduce injuries, decrease pain, optimize performance and speed recovery by turning complex science into simple, efficient and results-oriented applications accessible through a computer or personal digital device.
When paired with Stella's expertise in developing, deploying and scaling innovative capabilities within health care, Fusionetics' preventative solutions now have the potential to benefit self-insured employers, health plans, hospital systems and providers across the country.
Based in Minnesota, Stella is designed to nurture and scale differentiated businesses across the country to improve health in bold and innovative ways. It serves as the parent company for health insurer Blue Cross and Blue Shield of Minnesota and its subsidiaries and affiliate companies including Further and ClearStone Solutions Inc.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon